



NHIA Bamlanivimab Pilot Office Hours

Friday February 5, 2021



Agenda

- Program Update
 - Dashboard Overview
 - Reminder: Updated EUA
- Reimbursement Reminders

Program Updates

- Total Doses Infuse = 309
- 16 states and 48 cities with 79% of doses infused with population less than 100,000
- ECHO Calls
 - Next Week will feature a BAM Pilot Participant
 - Topic “Achieving Speed and Scale”
 - https://echo.zoom.us/webinar/register/WN_nJLmp2xaT-yNBHe-0Pfspw

Program Updates



- Updated Bamlanivimab EUA
 - 3 Areas of Change
 - Dose Preparation & Administration
 - Warning: Hypersensitivity (Anaphylaxis & IRR's)
 - Warning: Clinical Worsening After Bamlanivimab Administration
- Hypersensitivity (Anaphylaxis & IRR's)
 - Added Symptoms: Cardiac in nature (Afib, Tachy & Bradycardia, Arrhythmia)
- Warning: Clinical Worsening After Bamlanivimab Administration (**NEW!!!**)
 - Clinical worsening seen with fever, hypoxia, CV events, altered mental status
 - Not known if related to COVID-19 or Bamlanivimab

Update Preparation and Administration

Table 1: Recommended Dilution and Administration Instructions for Bamlanivimab^a

Drug: Add 20 mL of bamlanivimab (1 vial) to a prefilled infusion bag and administer as instructed below		
Size of prefilled 0.9% Sodium Chloride infusion bag	Maximum Infusion Rate	Minimum Infusion Time
50 mL	270 mL/hr	16 minutes
100 mL	270 mL/hr	27 minutes
150 mL	270 mL/hr	38 minutes
250 mL	270 mL/hr	60 minutes

^a 700 mg of bamlanivimab (20 mL) is added to an infusion bag and administered as a single intravenous infusion.

- Still Requires:
 - 0.2/0.22 micron filter
- Post-Infusion line flush (recommend 50ml NS)
- 1-Hr Post Infusion Monitoring Period
- Storage:
 - 24 hours Ref.
 - 7 hours Room Temp

Place of Service (POS) Update

Mass immunizer's should use POS 60 when billing for COVID treatments.

- Reference Medicare Internet Only Manual (IOM) Chapter 18 100-4 10.3.1
 - Item 24B: (Place of Service (POS)): Line 1: "60" Line 2: "60" NOTE: POS Code "60" must be used for roster billing.

All others should use the actual POS where the service was rendered – SNF, LTC, NF, ALF, etc.

Please contact bill.noyes@nhia.org with any claims processing issues.

COVID-19 Treatments Reimbursement Review for Home Infusion Pharmacies

- Must be enrolled to bill the A/B MAC, Pharmacy or Mass Immunizer
- When the monoclonal antibody COVID-19 product is given to providers and suppliers for free, the HCPCS code for the monoclonal antibody product should not be included on the claim.
- Medicare allowable for mAb administration is \$309.60.
- Administration is inclusive of supplies/equipment and services.
- Administration is billed by the entity that administers the product.
- No patient co-pay or deductible.
- Bill Medicare Advantage to A/B MAC

NHIA tool https://www.nhia.org/wp-content/uploads/2020/03/BAM-Pilot_Coding-Billing_v4.pdf

COVID-19 Treatment Resources

- CMS mAb Instructions <https://www.cms.gov/files/document/covid-medicare-monoclonal-antibody-infusion-program-instruction.pdf>
- CMS Enrollment <https://www.cms.gov/medicare/covid-19/enrollment-administering-covid-19-vaccine-shots>
- CMS HCPCS codes and rates <https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/covid-19-vaccines-and-monoclonal-antibodies>
- CMS FAQ (new) <https://www.cms.gov/files/document/03092020-covid-19-faqs-508.pdf> See BB. Drugs and Vaccines Under Part B – starts on page 120

Having claims processing issues? Need support?

Please contact Bill Noyes with any claims processing issues.

Bill Noyes

SVP of Reimbursement Policy, NHIA

bill.noyes@nhia.org

703-838-2661

